What NIH SBIR and STTR are for
NIH sets aside more than $1.4 billion of its research and development funding for its Small Business Programs, the SBIR and STTR awards it also calls America's Seed Fund [source]. The official focus is early-stage small businesses working on high-impact technologies "ranging from research tools to diagnostics, digital health, drugs, medical devices, and others," with the aim of taking innovations from "the bench to the bedside" [source].
NIH does not take ownership of the small business, and it is generally not the final purchaser of the technologies the programmes generate [source]. The money is for research, development and some commercialisation support, not a guaranteed procurement contract.
These awards are a poor fit if you do not have a health, biomedical or related brief, or if the applicant is not a qualifying U.S. small business. NSF SBIR and STTR, which we cover in NSF SBIR and STTR for AI startups, are the closer federal small-business route for many other AI companies. Do not treat an NIH prize challenge as an SBIR award: they are different instruments, with different rules.
SBIR versus STTR, and the funding paths
The scope of work can be the same; the partnership and employment rules are not. The money always goes to the small business, not to a university partner [source].
| SBIR | STTR | |
|---|---|---|
| Research-institution partner | Allowed, not required | Required, and the partner must be a non-profit research institution such as a university |
| Work requirement | The small business may outsource up to 33% of Phase I research and 50% of Phase II research | At least 40% of the work by the small business and 30% by the research-institution partner; the rest may be done by either, or outsourced |
| Principal investigator | Primary employment (more than 50%) should be with the small business | The PI must be employed by either the partnering research institution or the small business |
NIH also publishes several application paths. The phases are funding phases, and NIH is explicit that they are "separate from and not aligned with clinical trial phases" [source]:
- Phase I is for feasibility, technical merit and commercial potential.
- Phase II continues the work started in Phase I. You can apply once you have reached your Phase I milestones, even before Phase I ends, and up to six receipt dates after the Phase I budget period expires.
- Fast-Track lets you submit Phase I and Phase II as one application, which can shorten the gap between phases, but you need a fully developed Phase II plan at the outset.
- Direct to Phase II is for projects that have already demonstrated feasibility and have not received a Phase I SBIR or STTR, so you can skip Phase I.
- Phase IIB Strategic Breakthrough awards, offered by some NIH institutes and centres, are for Phase II projects that need more time and effort than a standard Phase II of two years.
- The Commercialisation Readiness Pilot (CRP) provides technical assistance and funding for late-stage development to awarded Phase II and Phase IIB small businesses.
NIH says you can begin with a Phase I, a Fast-Track, or a Direct to Phase II, depending on how much preliminary work you have already done, and it encourages you to talk to programme staff about the path [source].
Official budget guidelines
The budget guidelines are the same for NIH SBIR and STTR, but individual NIH institutes and centres can set their own limits [source]. The figures below are NIH's published guidelines, checked on 18 November 2026, not a promise of what any one institute will award:
- Phase I: $335,937, for a project lasting between six months and two years.
- Phase II: $2,239,578, for a project lasting between one and three years.
- Commercialisation Readiness Pilot: $4,479,156, for a project lasting up to three years.
Some biomedical topics have an SBA waiver that allows larger Phase I and Phase II awards. NIH tells applicants to read the institute, centre and office funding considerations for approved waiver topics, and to contact programme officials before submitting any application above the totals above [source]. Do not rely on third-party sites that quote a different "standard" Phase I cap; the figures here are from NIH's own Understanding SBIR and STTR page.
Who can apply
Only United States small business concerns may submit an SBIR or STTR application. A university or other research institution can be a subcontractor; it cannot be the applicant [source]. At the time of a Phase I and Phase II award, the concern must meet all of NIH's stated tests, including the Phase I to Phase II transition benchmark rate. In short, it must [source]:
- Be organised for profit, with a place of business in the United States, and operate primarily in the United States or make a significant contribution to the U.S. economy through taxes or the use of American products, materials or labour.
- Be an individual proprietorship, partnership, LLC, corporation, joint venture, association, trust or cooperative, with extra limits if it is a joint venture involving foreign business entities.
- Meet one of the ownership tests: more than 50% owned and controlled by U.S. citizens or permanent residents (or by other concerns that are), or, for SBIR only, more than 50% owned by multiple venture capital operating companies, hedge funds or private equity firms, with no single such firm owning more than 50% unless that firm itself qualifies as a small business owned by U.S. citizens or permanent residents; joint ventures have their own combination of those rules.
- Have, including affiliates, not more than 500 employees.
The principal investigator must legally reside in the United States and be available for the duration of the project [source]. Work outside the United States is only considered in rare, justified cases, and should be discussed with NIH staff before you apply; whenever possible, overseas work should be paid for with other funds [source].
UK or other non-U.S. companies cannot use this as a first-stop grant. If that is you, see UK grants for AI or ARIA funding explained.
What to do next
- Read NIH's Understanding SBIR and STTR page, then the eligibility criteria, then the current solicitations and the relevant institute's funding considerations, including any budget waiver topics.
- Decide whether SBIR or STTR fits the team. If the core science still lives in a university lab, STTR's required partnership may be the honest structure; if the company will do most of the work, SBIR may be simpler.
- Speak to the relevant NIH programme officer before you write a large or unusual budget, especially if you are considering Fast-Track, Direct to Phase II, or an amount above the guideline.
- If you also want a walk-through of the other major U.S. small-business R&D programme, use NSF SBIR and STTR for AI startups and how to write an NSF SBIR proposal. The proposal cultures differ; do not copy an NSF pitch onto an NIH form and hope.
We do not currently list an open NIH SBIR or STTR solicitation on the grants board (prize challenges are listed separately, and are not SBIR awards). Start from NIH's own programme pages, and watch our grants list for any NIH calls we add later.
